(Press-News.org) The 7th World Conference on Targeting Phage Therapy 2024 is set to take place on June 20-21 at the Corinthia Palace Malta, introducing the latest advancements within the field of phage research and therapy.
Robert T. Schooley, M.D., Professor of Medicine at the University of California, San Diego, and Co-Director of the Center for Innovative Phage Applications and Therapeutics, will lead the discourse, presenting insights and strategies essential to Phage Therapy in his talk titled "Phage Therapeutics 2024: Essential Translational Research Components for Clinical Trials."
Agenda at a Glance
Day One: will focus on Phages, Hosts & Microbiome, exploring current research on phageome, microbiome-phageome interactions, and the role of phages in various dysbiosis conditions. It will also shed light on emerging trends and innovative approaches in phage therapy, covering topics such as combating phage resistance, synthetic phages, and designing clinical studies.
Day Two: will feature sessions on the transition of phage research to clinical applications and a review of ethical and regulatory considerations in phage therapy.
Targeting Phage Therapy 2024 Speakers Line-Up
• Robert T. Schooley, University of California, San Diego, USA
Phage Therapeutics 2024: The Critical Role of Translational Research in Clinical Trials
• Jean-Paul Pirnay, Queen Astrid Military Hospital, Belgium
Magistral Phage Preparations: Is This the Model for Everyone?
• Barbara Brenner, Kanzlei BRENNER, Germany
Regulatory restrictions vs. Human Rights, the Hippocratic oath and the Freedom of therapy– The legal aspect of phage therapy
• Nannan Wu, Shanghai Public Health Clinical Center, Fudan University, China
Phage Therapy: A Glimpse into Clinical Studies Involving Over 150 Cases
• Graham F. Hatfull, University of Pittsburgh, USA
Mycobacteriophages and Their Therapeutic Potential
• Paul Turner, Yale University, USA
Selection for Phage Resistance Reduces Virulence of Shigella flexneri
• Pieter-Jan Ceyssens, Sciensano, Belgium
Quality control of phage Active Pharmaceutical Ingredients (APIs) in Belgium
• Wolfgang Weninger, Medical University of Vienna, Austria
The Phageome in Normal and Inflamed Human Skin
• Sabrina Green, KU Leuven, Belgium
Making Antibiotics Great Again: Phage resistance in vivo correlates to resensitivity to antibiotics in pan-resistant Pseudomonas aeruginosa
• Rodrigo Ibarra Chávez, University of Copenhagen, Denmark
Phage Satellites, a Diversity of Extradimensional Symbionts and Pathways to Phage Therapy
• Domenico Frezza, University of Roma Tor Vergata, Italy
Towards efficient phage therapies: investigation of phage / bacteria equilibrium with metagenome of dark matter in natural samples
• Eugene V Koonin, National Institutes of Health, USA
Evolution and megataxonomy of viruses: the place of phages in the virosphere
• Federica Briani, University of Milan, Italy
Addressing Phage Resistance to Enhance the Robustness of Phage Therapy for Pseudomonas aeruginosa Infections in Cystic Fibrosis Patients
• Jumpei Fujiki, University of California San Diego, USA
Phage therapy: Targeting intestinal bacterial microbiota for the treatment of Liver disease
Call For Abstract & Recognition of Excellence
Abstract submission for short oral and poster presentations is open. You can share your latest phage research and findings in front of an international audience during Targeting Phage Therapy 2024 in Malta.
Awards will be assigned to the best scientific contribution, best oral presentation, and best poster presentation. Abstract Submission Details.
Keeping Up with Phage Therapy 2024: Where to Find the Latest Updates
LinkedIn | Newsletter Archive/Subscription| 2024 Website
END
The 7th World Conference on Targeting Phage Therapy, taking place in Malta in 2024, will showcase current developments in phage therapy and offer strategic insights into its future directions
2024-03-20
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Companies reluctant to pay extra to confirm suppliers’ sustainability claims
2024-03-20
Many companies proclaiming ethical credentials resist paying a premium to test their suppliers’ sustainability claims, new research suggests.
A team from Bayes Business School (formerly Cass), City, University of London, studied responses from 234 managers with procurement decision-making powers.
While buyers’ purchasing decisions are not solely price-driven, the team found, they are often happy to accept suppliers’ reassurances about sustainability rather than pay a premium for third party verification. Despite accepting ...
Deep Earth electrical grid mystery solved
2024-03-20
To “breathe” in an environment without oxygen, bacteria in the ground beneath our feet depend upon a single family of proteins to transfer excess electrons, produced during the “burning” of nutrients, to electric hairs called nanowires projecting from their surface, found by researchers at Yale University and NOVA School of Science and Technology, NOVA University Lisbon (NOVA-FCT).
This family of proteins in essence acts as plugs that power these nanowires to create a natural electrical ...
Metformin during pregnancy affects the brain development in offspring mice
2024-03-20
With the rise in gestational diabetes and metabolic disorders during pregnancy, metformin is also being prescribed more frequently. Although it is known that the oral antidiabetic agent can cross the placental barrier, the impacts on the brain development of the child are largely unknown. An interdisciplinary research team from the German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE) have now been able to demonstrate in a mouse model that although metformin has positive effects in pregnant animals, it does not in the offspring. The results were published in the specialist journal ‘Molecular ...
Exposure to tobacco before birth significantly increased risk of Type 2 diabetes in adults
2024-03-20
Research Highlights:
Exposure to tobacco before birth and beginning smoking during childhood or adolescence were significantly associated with the development of Type 2 diabetes in adulthood, according to a study of nearly half a million adults in the UK Biobank.
Among those exposed to tobacco before birth or who began smoking during childhood or adolescence, participants who had a genetic predisposition to develop Type 2 diabetes and started smoking in childhood or adolescence had the highest risk of developing Type 2 diabetes.
Embargoed until 10:30 a.m. ...
In flies, a single brain cell can drive multiple movements of the body
2024-03-20
NEW YORK, NY — Motor neurons are the cells the brain uses to command muscles to act. Scientists typically thought of them as simple connections, much like the cables that link computers with their accessories. Now, in fly studies, researchers at Columbia's Zuckerman Institute have discovered that single motor neurons can each direct an insect’s body to move in far more complex ways than previously thought.
The findings were published in Nature on March 20.
"This is one of the first times scientists have analyzed in 3D what single motor neurons do ...
Toba supereruption unveils new insights into early human migration
2024-03-20
Modern humans dispersed from Africa multiple times, but the event that led to global expansion occurred less than 100,000 years ago. Some researchers hypothesize that dispersals were restricted to “green corridors” formed during humid intervals when food was abundant and human populations expanded in lockstep with their environments. But a new study in Nature, including ASU researchers Curtis Marean, Christopher Campisano, and Jayde Hirniak, suggests that humans also may have dispersed during arid intervals along “blue highways” created by seasonal rivers. Researchers also found evidence of cooking and stone tools that represent the oldest evidence of archery.
Working ...
Bacteria subtype linked to growth in up to 50% of human colorectal cancers, Fred Hutch researchers report
2024-03-20
Researchers at Fred Hutchinson Cancer Center have found that a specific subtype of a microbe commonly found in the mouth is able to travel to the gut and grow within colorectal cancer tumors. This microbe is also a culprit for driving cancer progression and leads to poorer patient outcomes after cancer treatment.
The findings, published March 20 in the journal Nature, could help improve therapeutic approaches and early screening methods for colorectal cancer, which is the second most common cause of cancer deaths in adults in the U.S. according to the American Cancer Society.
Examining colorectal cancer tumors removed from ...
Reducing the side effects of breast and ovarian cancer treatment
2024-03-20
Some anti-cancer treatments not only target tumour cells but also healthy cells. If their effects on the latter are too strong, their use can become limiting. A team from the University of Geneva (UNIGE), in collaboration with Basel-based FoRx Therapeutics, has identified the mechanism of action of PARP inhibitors, used in particular for breast and ovarian cancer in patients carrying the BRCA gene mutation. These inhibitors block two specific activities of the PARP proteins. By blocking one of them, the toxic effect on cancer cells is maintained, while healthy cells are preserved. This work, published in the journal Nature, will help improve the efficacy of these treatments.
Despite ...
Skeleton-wide study of blood cell formation yields surprising findings
2024-03-20
Imagine being able to count the different types of blood cells being formed inside the tiny bones of a mouse and pinpointing the strings and clusters of cells within the bone marrow that are responsible for producing specific types of blood cells.
That’s exactly what a team of scientists led by experts at Cincinnati Children’s achieved in a far-reaching study published March 20, 2024, in the prestigious journal Nature. Their work adds unprecedented new understanding of the “elegant” and “resilient” anatomy of bone marrow while also generating evidence of unexpected variations in how the skeleton ...
MD Anderson Research Highlights for March 20, 2024
2024-03-20
HOUSTON ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Recent developments at MD Anderson offer insights into a combination therapy that slows pancreatic cancer progression, an all-oral treatment for older patients with acute myeloid leukemia (AML) unable to receive intensive chemotherapy, novel targets to protect against osteoporosis and bone metastasis, the generation ...